ReviewMedicine2026
Presumed oxaliplatin-related Guillain-Barré syndrome: A case report and review of chemotherapy-related Guillain-Barré syndrome.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleOxaliplatin, a platinum-based chemotherapeutic widely used in colorectal, hepatobiliary, and pancreatic malignancies, commonly causes a symmetric, cold-induced sensory neuropathy. Rarely, it has been linked to immune-mediated Guillain-Barré Syndrome (GBS), which can be misattributed to drug-induced sensory neuropathy and delay diagnosis. Distinguishing the two is critical because GBS can progress to respiratory failure and death. PATIENT CONCERNS: A 77-year-old woman with concurrent metastatic cholangiocarcinoma and colorectal carcinoma developed acute, symmetric, ascending motor weakness with clinically preserved sensation approximately 2 weeks after her last cycle of gemcitabine, oxaliplatin, leucovorin, and 5-fluorouracil (GOLF), rapidly progressing to an inability to ambulate. DIAGNOSIS: Neurological examination and cerebrospinal fluid analysis (albuminocytologic dissociation) were consistent with GBS, and nerve conduction studies demonstrated absent motor and sensory responses, indicating a severe axonal variant (AMSAN); sensory involvement was electrodiagnostic rather than clinical. An extensive infectious, autoimmune, and paraneoplastic workup was negative, supporting a diagnosis of presumed oxaliplatin-related GBS; a Naranjo score of 4 indicated a "possible" drug association.
interventionsShe received 5 sessions of therapeutic plasma exchange followed by 4 sessions of intravenous immunoglobulin. OUTCOMES: No meaningful neurological recovery occurred; she developed progressive respiratory failure requiring mechanical ventilation and died. LESSONS: Clinicians should maintain a high index of suspicion for GBS in patients on platinum-based chemotherapy who develop abrupt, symmetric motor weakness after common causes have been ruled out. Because causality is difficult to establish, the association remains presumed; early recognition, prompt immunotherapy, and pharmacovigilance are essential to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.